Abstract:
:Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and secondary prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. In primary prevention, CARDS (Collaborative Atorvastatin Diabetes Study) showed that atorvastatin 10 mg/day (vs placebo) reduced relative risk of the composite primary endpoint (acute coronary heart disease [CHD] events, coronary revascularisation, or stroke) by 37% (p = 0.001). This decrease was similar to decreases in major cardiovascular events in the ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm) trial and HPS (Heart Protection Study). However, in CARDS, atorvastatin efficacy was evident as early as 6 months after starting treatment, whereas in HPS, simvastatin efficacy was noticeable only from about 15-18 months after starting treatment. In the ASCOT-LLA trial, in 2226 hypertensive diabetic patients without previous cardiovascular disease, atorvastatin (vs placebo) reduced the relative risk of all cardiovascular events and procedures by 25% (p = 0.038). In secondary prevention, substudies of the GREACE (GREek Atorvastatin and Coronary-heart-disease Evaluation), TNT (Treating to New Targets) and PROVE-IT (PRavastatin Or atorVastatin Evaluation and Infection Therapy) trials reported results for the approximately 15-25% of study participants who had diabetes. In the GREACE substudy, atorvastatin (vs physicians' standard care) significantly reduced the relative risk of total mortality by 52% (p = 0.049), coronary mortality by 62% (p = 0.042), coronary morbidity by 59% (p < 0.002) and stroke by 68% (p = 0.046). In the TNT substudy, incidence of the primary endpoint was significantly lower in diabetic patients treated with atorvastatin 80 mg/day rather than 10 mg/day (13.8% vs 17.9%; relative risk 0.75; p = 0.026). In the PROVE-IT substudy, a significantly lower incidence of acute cardiac events was reported for atorvastatin versus pravastatin recipients (21.1% vs 26.6%; p = 0.03) and, therefore, an absolute risk reduction of 5.5% was associated with atorvastatin therapy. ASPEN (Atorvastatin Study for Prevention of coronary heart disease Endpoints in Non-insulin-dependent diabetes mellitus) - a mixed primary and secondary prevention trial in diabetic patients - found that a 29% lower low-density lipoprotein-cholesterol level was seen with atorvastatin than placebo at endpoint (p < 0.0001); however, the reduction in composite primary endpoint of major cardiovascular events (cardiovascular mortality, nonfatal major cardiovascular event or stroke, and unstable angina requiring hospitalisation) with atorvastatin (13.7% vs 15.0% with placebo), and reduction in acute myocardial infarction relative risk of 27% with atorvastatin were not statistically significant. In CHD patients with metabolic syndrome (n = 5584) in a sub-analysis of the TNT trial, intensive versus lower-dosage atorvastatin therapy reduced the relative risk of major cardiovascular and cerebrovascular events by 29% (p < 0.0001). The analysis also revealed that CHD patients with, rather than those without, metabolic syndrome had a 44% greater level of absolute cardiovascular risk, thus clearly underscoring the clinical feasibility of administering intensive lipid-lowering therapy to CHD patients with metabolic syndrome. In summary, several patient populations, from definitive, large-scale studies, are now available to corroborate the integral place of atorvastatin--in line with various regional and internationally accepted disease management guidelines--in the primary and secondary prevention of cardiovascular events in patients with diabetes and/or metabolic syndrome.
journal_name
Drugsjournal_title
Drugsauthors
Arca Mdoi
10.2165/00003495-200767001-00005subject
Has Abstractpub_date
2007-01-01 00:00:00pages
43-54eissn
0012-6667issn
1179-1950pii
6715journal_volume
67 Suppl 1pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::Chronic hand eczema is a common but frequently disabling skin condition which poses a significant social and economic burden. Although skin protection measures and topical therapies are fundamental in its management, some patients are refractory to first-line therapy with topical corticosteroids and require systemic t...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0621-0
更新日期:2016-09-01 00:00:00
abstract::With changing donor characteristics and the growing shortage in organ supply, renal transplant practitioners have sought to optimize the use of expanded criteria donor (ECD) kidneys, which have poorer outcomes than standard criteria donor (SCD) kidneys. The outcomes may represent an acceptable trade-off if ECD transpl...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200868001-00006
更新日期:2008-01-01 00:00:00
abstract:UNLABELLED:Oral delayed-release mesalazine is an enteric-coated formulation which releases mesalazine in the terminal ileum and colon. Up to 74% of patients with mild to moderately active ulcerative colitis experience endoscopic or symptomatic improvement (including remission) or both when treated with oral delayed-rel...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199957030-00013
更新日期:1999-03-01 00:00:00
abstract::Asthmatic patients during sympton-free periods almost invariably have abnormalities in lung mechanics and gas exchange. Tentacious secretions and mucosal thickening exaggerate maldistribution of ventilation and cause flow limitation in small airways. Hence, the maximal expiratory flow volume loop in these patients wil...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-197816030-00007
更新日期:1978-09-01 00:00:00
abstract:UNLABELLED:Tranexamic acid is a synthetic derivative of the amino acid lysine that exerts its antifibrinolytic effect through the reversible blockade of lysine binding sites on plasminogen molecules. Intravenously administered tranexamic acid (most commonly 10 mg/kg followed by infusion of 1 mg/kg/hour) caused reductio...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199957060-00017
更新日期:1999-06-01 00:00:00
abstract::An acute thrombus at the site of an atherosclerotic obstruction is the usual cause of myocardial infarction. Thrombolytic therapy is an exciting new therapy for reducing the extent of myocardial infarction by lysing intracoronary clots. Such therapy has now been widely applied by: prolonged intravenous infusion of str...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198428050-00004
更新日期:1984-11-01 00:00:00
abstract::The discovery of at least 2 cyclo-oxygenase (COX) isoenzymes, referred to as COX-1 and COX-2, has updated our knowledge of nonsteroidal anti-inflammatory drugs (NSAIDs). This has lead investigators to reconsider what can be awaited from this class of drugs. The 2 COX isoenzymes share structural and enzymatic similarit...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199753040-00003
更新日期:1997-04-01 00:00:00
abstract::The pharmacological treatment of epilepsy has made considerable progress during the last decade, due to improved knowledge of the clinical pharmacology of individual drugs, acquisition of new information on the factors affecting response and need for drug treatment, and development of promising new agents. Once a clin...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199549050-00004
更新日期:1995-05-01 00:00:00
abstract::Intravenous landiolol [Rapibloc® (EU)], an ultra short-acting highly cardioselective β1-blocker, is approved in the EU for the rapid short-term control of tachyarrhythmias in the perioperative and intensive care settings. It has long been used in Japan to treat perioperative tachyarrhythmias. The efficacy of landiolol...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-0883-9
更新日期:2018-03-01 00:00:00
abstract::Arrhythmia treatment has always been difficult, particularly as there are no good indicators of the optimal management strategy. The introduction of new antiarrhythmic agents has forced reappraisal of how these drugs are used. Dynamic electrocardiography and invasive electrophysiological studies are important tools fo...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198836050-00005
更新日期:1988-11-01 00:00:00
abstract::Azelnidipine is a new dihydropyridine calcium channel antagonist with selectivity for L-type calcium channels that has recently been approved in Japan for the treatment of patients with hypertension. Results from clinical trials showed that, in 95 patients with mild-to-moderate hypertension, long-term treatment with a...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200363230-00004
更新日期:2003-01-01 00:00:00
abstract::Chronic pancreatitis is a clinical entity that results from the progressive inflammation and irreversible fibrosis of the pancreas resulting from the cumulative injury sustained by the pancreas over time. It is an illness with variable presentations that can severely impact quality of life, while its long-term complic...
journal_title:Drugs
pub_type: 杂志文章
doi:10.1007/s40265-020-01360-6
更新日期:2020-08-01 00:00:00
abstract::The effects of enalapril on clinical well-being, treadmill exercise performance, haemodynamic measurements, hormone levels, and plasma biochemistry in patients with moderate heart failure, were assessed in a 12-week placebo-controlled, double-blind study. Maintenance frusemide and digoxin treatment was continued throu...
journal_title:Drugs
pub_type: 临床试验,杂志文章
doi:10.2165/00003495-198500301-00011
更新日期:1985-01-01 00:00:00
abstract:INTRODUCTION:Several pharmacological treatments aiming at a better symptomatic control of osteoarthritis (OA) are used in daily practice but their efficacy is often disputed. The purpose of this network meta-analysis (NMA) is to assess the efficacy on pain and function of the drugs that are most widely prescribed again...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01423-8
更新日期:2020-12-01 00:00:00
abstract::Many drugs alter the anticoagulant effect of oral coumarins. It is essential that physicians be aware of interactions leading to increased or decreased anticoagulation or to erratic control. Interacting drugs can be classified as influencing the pharmacodynamics (pharmacological actions) or the pharmacokinetics (absor...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197611060-00006
更新日期:1976-01-01 00:00:00
abstract::Anidulafungin is an antifungal drug belonging to the echinocandin class with a potent in vitro fungicidal activity against a wide range of Candida species, including C. glabrata and C. krusei. Anidulafungin is also active in vitro against moulds belonging to the genus Aspergillus and some dematiaceous genera. Furtherm...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11315560-000000000-00000
更新日期:2009-01-01 00:00:00
abstract::This paper reviews the evidence that, in patients with hypertension, end-organ damage correlates more closely with blood pressure values obtained by ambulatory blood pressure monitoring than with those obtained by conventional sphygmomanometry. However, ambulatory blood pressure monitoring is not suitable for routine ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199200441-00004
更新日期:1992-01-01 00:00:00
abstract::The efficacy of cilazapril monotherapy was evaluated in 2 multicentre double-blind dose-response trials. After 4 weeks of a single-blind placebo run-in period, patients with uncomplicated mild to moderate essential hypertension and a sitting diastolic blood pressure of 100 to 115 mm Hg, 24 hours after the last placebo...
journal_title:Drugs
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.2165/00003495-199100411-00007
更新日期:1991-01-01 00:00:00
abstract::Acute renal failure (ARF) occurs frequently in hospitalised patients, and is associated with significant morbidity and mortality. The most common and generalised forms of acute renal failure are pre-renal conditions and intra-renal acute tubular necrosis (ATN). Pre-renal ARF in its pure state should be entirely revers...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200059010-00005
更新日期:2000-01-01 00:00:00
abstract::During the last 2 decades, there has been a dramatic increase in the use of strong opioids for chronic non-cancer pain. This increase has been accompanied by a steep increase in abuse, misuse, and both fatal and non-fatal overdoses involving prescription opioids. The situation is already alarming in the US. Prescripti...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11635860-000000000-00000
更新日期:2012-09-10 00:00:00
abstract::Acitretin (etretin), a second generation monoaromatic retinoid for use in the treatment of severe psoriasis and other dermatoses, is the major active metabolite of etretinate and possesses a similar therapeutic index; i.e. a similar ratio of clinical efficacy to adverse effects. When used alone at a maintenance dosage...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199243040-00010
更新日期:1992-04-01 00:00:00
abstract::Levocetirizine (Xyzal) is a selective, potent, oral histamine H(1) receptor antagonist of the latest generation that is licensed for the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis [PER]) and chronic idiopathic urticaria (CIU). Large, well designed trials indicate that levocetiri...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666070-00017
更新日期:2006-01-01 00:00:00
abstract::The treatment of acute upper gastrointestinal bleeding is becoming more dependent upon early diagnosis. For the majority of patients whose bleeding has stopped when they come to the physician's attention, treatment for peptic disorders remains the mainstay of therapy. For patients who present to the physician actively...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198937010-00007
更新日期:1989-01-01 00:00:00
abstract::Desloratadine is the orally active major metabolite of the nonsedating H1-antihistamine loratadine. The drug had no adverse cardiovascular effects in various animal models or when administered at 9 times the recommended adult dosage for 10 days in volunteers. Therapeutic dosages had no effects on wakefulness or psycho...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-200161060-00007
更新日期:2001-01-01 00:00:00
abstract::25 patients have been included in a randomised trial aimed to compare prehospital and hospital administration of anisoylated plasminogen streptokinase activator complex (AP-SAC). Patients were first seen, at home, by a noncardiologist doctor working in a mobile-care unit and were then evaluated for entry into the stud...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198700333-00042
更新日期:1987-01-01 00:00:00
abstract::ZD1839 ('Iressa') is an orally active, selective epidermal growth factor receptor-tyrosine kinase inhibitor which blocks signal transduction pathways implicated in the proliferation and survival of cancer cells and other host-dependent processes promoting cancer growth. In preclinical studies, ZD1839 produced reversib...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200060001-00004
更新日期:2000-01-01 00:00:00
abstract::Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). By silencing the gene encoding glycolate oxidase, ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01463-0
更新日期:2021-01-06 00:00:00
abstract::Iloprost is an analogue of epoprostenol (prostacyclin; PGI2; a potent but short-lived prostanoid mainly produced in the vascular endothelium) and mimics the pharmacodynamic properties of this compound, namely: inhibition of platelet aggregation, vasodilatation and, as yet ill-defined, cytoprotection. Improved metaboli...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199243060-00008
更新日期:1992-06-01 00:00:00
abstract:UNLABELLED:Enoxaparin (enoxaparin sodium) is a low molecular weight heparin (LMWH) that is widely used in the prevention of deep venous thrombosis and pulmonary embolism in patients undergoing orthopaedic or general surgery. Its efficacy in these indications has led to study of its use in patients with coronary artery ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199856020-00013
更新日期:1998-08-01 00:00:00
abstract::Guillain-Barré syndrome (GBS) is clinically defined as an acute peripheral neuropathy causing limb weakness that progresses over a time period of days or, at the most, up to 4 weeks. GBS occurs throughout the world with a median annual incidence of 1.3 cases per population of 100 000, with men being more frequently af...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200464060-00003
更新日期:2004-01-01 00:00:00